Royal Bank Of Canada Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target reduced by Royal Bank Of Canada from $31.00 to $30.00 in a research note issued to investors on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on the company. Mizuho upgraded ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $29.00 to $35.00 in a research note on Monday, February 23rd. Citigroup upped their target price on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Piper Sandler set a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, December 16th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 3rd. Finally, Stifel Nicolaus dropped their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $30.74.

ACADIA Pharmaceuticals Trading Down 0.3%

Shares of ACADIA Pharmaceuticals stock opened at $24.56 on Thursday. The firm’s 50 day simple moving average is $25.53 and its two-hundred day simple moving average is $24.44. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 8.69 and a beta of 0.66. ACADIA Pharmaceuticals has a 12-month low of $13.40 and a 12-month high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 13.96%. The firm had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. During the same period in the previous year, the company earned $0.86 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. On average, sell-side analysts predict that ACADIA Pharmaceuticals will post 0.7 EPS for the current fiscal year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. The trade was a 47.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 26.50% of the stock is currently owned by company insiders.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACAD. Farther Finance Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 386 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $26,000. Transamerica Financial Advisors LLC increased its stake in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,185 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.